Shots:
- Samsung Bioepis, in partnership with Harrow, has relaunched Byooviz, a biosimilar to Lucentis (ranibizumab), in the US
- Byooviz was initially commercialized by Biogen beginning in Jun 2022, before Biogen returned the US commercial rights to Samsung Bioepis at the end of 2025
- Approved by the FDA in 2021 as the first ophthalmology biosimilar, Byooviz treats wet Age-Related Macular Degeneration, Macular Edema following Retinal Vein Occlusion, & Myopic Choroidal Neovascularization, & received interchangeability designation in 2023
Ref: Businesswire | Image: Samsung Bioepis & Harrow | Press Release
Related News: Samsung Bioepis Reports Clinical Data on SB27 (Biosimilar, Keytruda)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
